Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54


Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.

Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T.

Value Health. 2020 Jan;23(1):61-73. doi: 10.1016/j.jval.2019.08.002. Epub 2019 Sep 25.


Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet SELP Splice QTL.

Rondina MT, Voora D, Simon LM, Schwertz H, Harper JF, Lee O, Bhatlekar SC, Li Q, Eustes AS, Montenont E, Campbell RA, Tolley ND, Kosaka Y, Weyrich AS, Bray PF, Rowley JW.

Circ Res. 2020 Feb 14;126(4):501-516. doi: 10.1161/CIRCRESAHA.119.315215. Epub 2019 Dec 19.


Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention.

Friede KA, Voora D.

Cardiovasc Res. 2019 Aug 1;115(10):1452-1453. doi: 10.1093/cvr/cvz110. No abstract available.


Pilot study of myocardial ischemia-induced metabolomic changes in emergency department patients undergoing stress testing.

Limkakeng AT Jr, Henao R, Voora D, O'Connell T, Griffin M, Tsalik EL, Shah S, Woods CW, Ginsburg GS.

PLoS One. 2019 Feb 1;14(2):e0211762. doi: 10.1371/journal.pone.0211762. eCollection 2019.


Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.

Peyser B, Perry EP, Singh K, Gill RD, Mehan MR, Haga SB, Musty MD, Milazzo NA, Savard D, Li YJ, Trujilio G, Voora D.

Circ Genom Precis Med. 2018 Sep;11(9):e002228. doi: 10.1161/CIRCGEN.118.002228.


Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study.

Parker WAE, Eriksson N, Becker RC, Voora D, Åkerblom A, Himmelmann A, James SK, Wallentin L, Storey RF; PLATO Investigators.

Platelets. 2019;30(5):579-588. doi: 10.1080/09537104.2018.1478404. Epub 2018 May 31.


Future directions in pharmacogenomics discovery in cardiovascular disease.

Friede KA, Voora D.

Pharmacogenomics. 2018 Apr;19(5):375-377. doi: 10.2217/pgs-2018-0002. Epub 2018 Mar 23. No abstract available.


Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events.

Wingrove JA, Fitch K, Rhees B, Rosenberg S, Voora D.

BMC Med Genomics. 2018 Jan 12;11(1):1. doi: 10.1186/s12920-017-0318-6.


An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.

Lucas JE, Bazemore TC, Alo C, Monahan PB, Voora D.

PLoS One. 2017 Nov 20;12(11):e0187809. doi: 10.1371/journal.pone.0187809. eCollection 2017.


Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network.

JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.


The need for sex-specific precision biomarkers for antiplatelet therapies.

Friede K, Voora D.

Future Cardiol. 2017 Aug 23. doi: 10.2217/fca-2017-0043. [Epub ahead of print] No abstract available.


The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association.

Musunuru K, Ingelsson E, Fornage M, Liu P, Murphy AM, Newby LK, Newton-Cheh C, Perez MV, Voora D, Woo D; American Heart Association Committee on Molecular Determinants of Cardiovascular Health of the Council on Functional Genomics and Translational Biology and Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Stroke Council.

Circ Cardiovasc Genet. 2017 Aug;10(4). pii: e000037. doi: 10.1161/HCG.0000000000000037. Review.


Transcription Factor RUNX1 Regulates Platelet PCTP (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events: Differential Effects of RUNX1 Variants.

Mao G, Songdej N, Voora D, Goldfinger LE, Del Carpio-Cano FE, Myers RA, Rao AK.

Circulation. 2017 Sep 5;136(10):927-939. doi: 10.1161/CIRCULATIONAHA.116.023711. Epub 2017 Jul 4.


Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.

Haga SB, Moaddeb J, Mills R, Voora D.

Pharmacogenomics. 2017 Mar;18(4):327-335. doi: 10.2217/pgs-2016-0175. Epub 2017 Feb 22.


An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.

Voora D, Coles A, Lee KL, Hoffmann U, Wingrove JA, Rhees B, Huang L, Daniels SE, Monane M, Rosenberg S, Shah SH, Kraus WE, Ginsburg GS, Douglas PS.

Am Heart J. 2017 Feb;184:133-140. doi: 10.1016/j.ahj.2016.11.004. Epub 2016 Nov 15.


Circulating extracellular vesicles containing miRNAs may have utility as early biomarkers for cardiac injury.

Doran B, Voora D.

Ann Transl Med. 2016 Oct;4(Suppl 1):S60. No abstract available.


Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.

Friede K, Li J, Voora D.

Clin Chem. 2017 Jan;63(1):177-185. doi: 10.1373/clinchem.2016.255232. Epub 2016 Nov 18. Review.


Rationale and design of the SLCO1B1 genotype guided statin therapy trial.

Singh K, Peyser B, Trujillo G, Milazzo N, Savard D, Haga SB, Musty M, Voora D.

Pharmacogenomics. 2016 Nov;17(17):1873-1880. doi: 10.2217/pgs-2016-0065. Epub 2016 Nov 3. No abstract available.


Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.

Voora D, Rao AK, Jalagadugula GS, Myers R, Harris E, Ortel TL, Ginsburg GS.

EBioMedicine. 2016 Sep;11:157-164. doi: 10.1016/j.ebiom.2016.08.021. Epub 2016 Aug 14.


Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects.

Voora D, Shah SH.

J Am Coll Cardiol. 2016 Mar 15;67(10):1211-1213. doi: 10.1016/j.jacc.2016.01.022. No abstract available.

Supplemental Content

Loading ...
Support Center